According to the
latest market report published by Future Market Insights
titled‘Keloid Treatment Market: Global Industry Analysis
(2012-2016) and Opportunity Assessment (2017-2027),’the global
keloid treatment market is estimated to be worth US$ 3,145.8 Mn by
2017 end, and is expected to expand at a CAGR of 3.4% over the
forecast period of 2017–2027 to reach a market valuation of US$
4,414.6 Mn by the end of 2027.
The global keloid
treatment market growth is substantially driven by the rising
prevalence of keloid scars as well as the development of multiple
keloids. A growing consciousness among patients regarding their
appearance is also driving the market of keloid treatment as keloid
scars on the exposed body parts leads to ugly appearances. Other
factors that are driving the growth in the keloid treatment market
include increasing reimbursement for keloid therapies, formalisation
of standard treatment guidelines for keloid and increasing use of
combination therapies. Clinics and hospitals are focussing on the
adoption of advanced therapy options. CryoShape is used to reduce the
impact of keloid scar and recurrence rate. Sensus Healthcare has
developed an advanced superficial radiation therapy device to impart
better treatment with limited adverse reactions.
Report overview@
https://www.futuremarketinsights.com/reports/keloid-treatment-market
The global keloid
treatment market is segmented based on treatment type, end user and
region. On the basis of treatment type, the market has been segmented
intoocclusive dressing, compression therapy, cryosurgery, excision,
radiation therapy, laser therapy, interferon therapy, intralesional
corticosteroid injection and others. Other treatment options include
dermal fillers, topical creams, 5-fluorouracil, retinoic acid and
imiquimod. Intralesional corticosteroid injection treatment segment
dominates the global keloid treatment market as this procedure is
considered the gold standard and is being used in combination with
other therapies. Intralesional corticosteroid injection is expected
to be the second most lucrative segment by treatment type, with a
market attractiveness index of 2.1 during the forecast period.
Based on end user,
the global keloid treatment market is segmented into hospitals,
dermatology clinics, ambulatory surgical centres and others.
Thehospitals segment is expected to remain dominant, as most of the
radiation therapies and excision procedures are performed in
hospitals. Hospitals is the largest segment by end user, which is
estimated to represent US$ 1,164.7 Mn, or 37.0% share of the total
market in 2017 and is projected to reach a market valuation of US$
1,643.8 Mn, or 37.2% share of the total market by the end of 2027,
expanding at a CAGR of 3.5% in terms of value.
Request to sample
report@
https://www.futuremarketinsights.com/reports/sample/rep-gb-1313
On the basis of
region, the global keloid treatment market is segmented into North
America, Latin America, Western Europe, Eastern Europe, Asia Pacific
excluding Japan, Japan and the Middle East & Africa.
North America
dominated the global keloid treatment market in 2016 and is expected
to continue to dominate the global market throughout the forecast
period. North America is the largest region in keloid treatment
market, which is estimated to represent US$ 1,105.6 Mn, or 35.1%
share of the total market in 2017 and is projected to reach a market
valuation of US$ 1,549.6 Mn, or 35.1% of the total market by the end
of 2027, expanding at CAGR of 3.4% in terms of value. Clinics in
North America are opting advanced treatment therapies that can aid in
reduced risk of recurrence.
Leading players in
the global keloid treatment market are launching new portable and
mobile radiation therapy devices and are offering better treatment
options to patients. Companies are targeting dermatology clinics to
market their devices, where patients are provided the first line of
treatment for keloid. Some of the players operating in the global
keloid treatment market who have been profiled in the report include
Novartis AG, Sensus Healthcare, RXi Pharmaceuticals, Inc., Sonoma
Pharmaceuticals, Inc., Perrigo Company plc, Bristol-Myers Squibb
Company, Pacific World Corporation, Valeant Pharmaceuticals
International, Inc., Revitol Corporation and Avita Medical Limited.
Request report
toc@
https://www.futuremarketinsights.com/reports/keloid-treatment-market/toc
ABOUT US:
Future Market
Insights (FMI) is a leading market intelligence and consulting firm.
We deliver syndicated research reports, custom research reports and
consulting services, which are personalized in nature. FMI delivers a
complete packaged solution, which combines current market
intelligence, statistical anecdotes, technology inputs, valuable
growth insights, an aerial view of the competitive framework, and
future market trends.
CONTACT:
Future Market
Insights
616 Corporate Way,
Suite 2-9018,
Valley Cottage, NY
10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email:
sales@futuremarketinsights.com
Website:
www.futuremarketinsights.com
